ArticleScientific reports2025
The efficacy of bone marrow-derived mesenchymal stem cells in restoring limbal stem cell deficiency in rat model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This approach aimed to assess the therapeutic significance of BM-MSCs in alleviating LSCD elicited in rats via corneal alkali burns and to explore the associated repairing mechanisms. Rats were assigned to (1) control group, (2) alkali burn group, and (3) stem cells group. Corneal surface investigations were performed using a slit lamp and fluorescence tests. The therapeutic impact of BM-MSCs was appraised by estimating the protein levels of TNF-α, SOD, VEGF, MMP-2, and IL-8 using ELISA. Moreover, mRNA transcription levels of corneal TNF-α, NF-kB, COX-2, and caspase-3 were quantified. Histological investigation and immunostaining of corneal cytokeratin 3 and p63 proteins were also conducted. The results indicated that BM-MSCs treatment enhanced the corneal wound healing, decreased corneal opacity, and neovascularization. Moreover, such treatment resulted in a significant decline in corneal TNF-α, IL-8, VEGF, and MMP-2 protein levels. Additionally, stem cells group elicited a significant down-expression of TNF-α, NF-κB, COX-2, and caspase-3 genes. Besides, BM-MSCs treatment restored the corneal epithelial integrity and ameliorated the pathological characteristics, as confirmed by histological and immunohistochemical analysis. Conclusively, the present investigation underscores the healing ability of BM-MSCs in LSCD in the rat model by repairing the damaged corneal epithelium through withstanding inflammation, angiogenesis, and apoptosis. Consequently, MSCs transplantation represents a promising therapeutic modality for LSCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.